<DOC>
	<DOCNO>NCT00770874</DOCNO>
	<brief_summary>This study open-label , multicenter , multinational , two-arm , parallel randomize Phase 3 study evaluate efficacy safety S-1+Cisplatin versus single-agent Cisplatin patient stage IVB , recurrent persistent carcinoma cervix .</brief_summary>
	<brief_title>Phase III Study S-1 + Cisplatin v Cisplatin Cervical Cancer</brief_title>
	<detailed_description>Japanese phase II study S-1 cervical cancer suggest promising response rate good tolerability . Since recommend chemotherapy metastatic recurrent cervical carcinoma either single-agent Cisplatin Cisplatin-based combination chemotherapy , design evaluate efficacy safety S-1 combination Cisplatin compare single-agent Cisplatin .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patients histologically proven cervical carcinoma ( All histological subtype include ) . Patients stage IVB , recurrent persistent disease . Patients amenable curative treatment surgery and/or radiotherapy . Patients receive chemotherapy chemoradiotherapy diagnosis recurrent , persistent , stage IVB disease . If patient receive chemotherapy , radiotherapy chemoradiotherapy previous treatment , follow interval must elapse last administration treatment : 1 . Chemotherapy : 21 day 2 . Radiotherapy : 21 days* 3 . Chemoradiotherapy : 42 days* If residual disease previously irradiate field without disease progression since ( chemo ) radiotherapy , 90 day must elapse last administration irradiation . Patients adequate hematologic , hepatic renal function define : Hemoglobin : ≥ 8.0 g/dL Neutrophil count : ≥ 2,000/mm^3 Platelet count : ≥ 100,000/mm^3 Total serum bilirubin : ≤ 1.5 time upper limit normal ( ULN ) AST ( GOT ) , ALT ( GPT ) : ≤ 2.5 time ULN . If abnormal value associate hepatic metastasis : ≤ 5.0 time ULN Serum creatinine : ≤ ULN creatinine clearance : ≥ 50 ml/min Patients ECOG performance status : 01 . Age : ≥ 20 year old . Patients take pill orally . Patients sign write consent form . Patients know hypersensitivity 5FU Cisplatin . Patients receive concomitant treatment drug interact S1 . Patients receive concomitant treatment drug interact Cisplatin . Patients administer investigational product within 30 day initiation study treatment . Patients previously treat S1 . Patients receive platinumcontaining chemotherapy chemoradiotherapy whose disease progress therapy . Patients suffer active infection ( e.g . fever ≥ 38°C ) . Patients serious complication . Patients bleed require hemostasis treatment . Patients bilateral hydronephrosis alleviate ureteral stent percutaneous drainage . Patients uncontrolled pleural effusion and/or ascites require drainage least twice week . Patients symptomatic brain metastasis history brain metastasis . Patients unmanageable bowel movement ( ex . Watery stool , chronic constipation ) . Patients active double cancer . Patients pregnant lactate . Patients consider inappropriate subject study investigator .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>